PerkinElmer (PKI) Research Coverage Started at Wolfe Research
Wolfe Research initiated coverage on shares of PerkinElmer (NYSE:PKI) in a research report released on Thursday morning, Briefing.com Automated Import reports. The brokerage issued a peer perform rating on the medical research company’s stock.
Other research analysts have also issued reports about the stock. Goldman Sachs Group raised shares of PerkinElmer from a neutral rating to a buy rating and set a $115.00 price objective on the stock in a research note on Tuesday, April 9th. Zacks Investment Research raised shares of PerkinElmer from a hold rating to a buy rating and set a $109.00 price objective on the stock in a research note on Wednesday, April 3rd. Royal Bank of Canada reaffirmed a hold rating and issued a $41.00 price objective on shares of PerkinElmer in a research note on Friday, May 3rd. UBS Group set a $92.00 price objective on shares of PerkinElmer and gave the company a hold rating in a research note on Saturday, February 2nd. Finally, Piper Jaffray Companies raised their price objective on shares of PerkinElmer to $104.00 and gave the company an overweight rating in a research note on Friday, February 1st. Ten investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $81.32.
PerkinElmer stock opened at $86.34 on Thursday. PerkinElmer has a 1-year low of $71.31 and a 1-year high of $103.00. The firm has a market capitalization of $9.53 billion, a price-to-earnings ratio of 23.92, a price-to-earnings-growth ratio of 1.52 and a beta of 1.22. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.17 and a current ratio of 1.68.
The company also recently announced a quarterly dividend, which will be paid on Friday, August 9th. Stockholders of record on Friday, July 19th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Thursday, July 18th. This represents a $0.28 annualized dividend and a dividend yield of 0.32%. PerkinElmer’s dividend payout ratio is currently 7.76%.
In other news, insider Joel S. Goldberg sold 24,465 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $92.81, for a total value of $2,270,596.65. Following the completion of the sale, the insider now owns 84,277 shares in the company, valued at $7,821,748.37. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Daniel R. Tereau sold 1,200 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $93.27, for a total transaction of $111,924.00. Following the completion of the sale, the insider now owns 5,839 shares of the company’s stock, valued at approximately $544,603.53. The disclosure for this sale can be found here. In the last quarter, insiders sold 53,156 shares of company stock valued at $5,041,217. 1.80% of the stock is currently owned by corporate insiders.
Hedge funds have recently made changes to their positions in the company. Quadrant Capital Group LLC purchased a new stake in PerkinElmer during the first quarter worth about $25,000. Lindbrook Capital LLC purchased a new stake in PerkinElmer during the fourth quarter worth about $25,000. Northwestern Mutual Wealth Management Co. increased its holdings in PerkinElmer by 237.2% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 381 shares of the medical research company’s stock worth $37,000 after buying an additional 268 shares during the last quarter. Citizens Financial Group Inc RI purchased a new stake in PerkinElmer during the fourth quarter worth about $32,000. Finally, Golden State Wealth Management LLC purchased a new stake in PerkinElmer during the first quarter worth about $42,000. Institutional investors own 95.49% of the company’s stock.
PerkinElmer Company Profile
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Read More: Back-End Load
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.